MedTrace Logo

18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer

NCT01993160 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-01-13

No results posted yet for this study

Summary

This is a single centre, single arm feasibility study of 18FCH PET-MR imaging for staging patients with high risk prostate cancer.

Study Hypothesis:

FCH-PET/MR will enable more accurate staging of patients with high risk prostate cancer as compared to conventional imaging.

Conditions

Interventions

DRUG

Fluorocholine (18F-FCH) Injection

Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)

RADIATION

PET scan

A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI

RADIATION

Whole body MRI

A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.

Sponsors & Collaborators

  • Prostate Cancer Canada

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Ur Metser, MD · University Health Network, Toronto

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01993160 on ClinicalTrials.gov